- |||||||||| Avastin (bevacizumab) / Roche, intetumumab (CNTO 95) / J&J
Biomarker, Trial completion, Enrollment change, Combination therapy: Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors (clinicaltrials.gov) - Mar 11, 2015
P1, N=13, Completed,
Active, not recruiting --> Completed | N=54 --> 13
- |||||||||| Avastin (bevacizumab) / Roche, intetumumab (CNTO 95) / J&J
Biomarker, Trial primary completion date, Combination therapy: Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors (clinicaltrials.gov) - May 12, 2014
P1, N=54, Active, not recruiting,
Active, not recruiting --> Completed | N=54 --> 13 Trial primary completion date: Mar 2014 --> Dec 2014
- |||||||||| Avastin (bevacizumab) / Roche, intetumumab (CNTO 95) / J&J
Biomarker, Trial completion date, Combination therapy: Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors (clinicaltrials.gov) - May 12, 2014
P1, N=54, Active, not recruiting,
Trial primary completion date: Mar 2014 --> Dec 2014 Trial completion date: Mar 2014 --> Dec 2014
- |||||||||| Avastin (bevacizumab) / Roche, intetumumab (CNTO 95) / J&J
Biomarker, Enrollment closed, Combination therapy: Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors (clinicaltrials.gov) - Apr 3, 2013
P1, N=54, Active, not recruiting,
Trial completion date: Mar 2014 --> Dec 2014 Recruiting --> Active, not recruiting
|
